AuntMarie,True,2019-05-31 14:33:00,0.5629,CYTR NK NH NK Abstracts some asked me to post abstractsascoorg239Sind
AuntMarie,True,2019-05-31 13:52:00,0.563,CYTR NK NH ASCO late breaking abstract update blurb fiercepharmacompharmaasc 200pm est is when the abstracts come out
AuntMarie,True,2019-05-31 12:18:00,0.555,NK NH CYTR well as often happensNK gets downgraded by tutes and we are announcing that we have 78 Complete response of patients in our bladder cancer clinical trial may the world winsoon has his own plans i think for NKmaybe we will find out what they are ultimately keep living patients i am rooting for you and your families
AuntMarie,True,2019-05-31 12:13:00,0.555,NK NH CYTR the current list of nantkwest clin trials remember that all soon comps are interelated thank you to all the study participants and families it saddens me to see a study that is withdrawn becuase the patient has died my heartfelt sympathy to the family and thank you for participating and trying to help mankind clinicaltrialsgovct2resu
AuntMarie,True,2019-05-31 11:51:00,0.562,NH still here and holding
AuntMarie,True,2019-05-31 11:03:00,0.5648,CYTR NK NH The ASCO Abstracts for those interested some of the results are excellent all soon companies are interelated holding super long abstractsascoorg239Sind
AuntMarie,True,2019-05-31 11:00:00,0.5648,CYTR NK NH One of the ASCO abstracts this one is bladder cancer abstractsascoorg239inde nine patients 82 have a reported CR In addition seven out of nine 78 patients in Cohort A demonstrated CR at their 6month response assessment Of thirteen evaluable patients in Cohort B ten patients 77 showed no evidence of recurrence at their 3month response assessment of these none 08 evaluated past 3 months have had disease recurrence Three serious adverse events AEs have been reported E coli infection anemia and bacteremia with no immunerelated AEs Conclusions Nine out of eleven 82 patients with BCGunresponsive CIS of the bladder demonstrated a complete response Ten out of thirteen patients with BCGunresponsive papillary NMIBC show no evidence of disease at first assessment Intravesical N803 plus BCG was welltolerated and no patients experienced immunerelated AEs Clinical trial information NCT03022825
AuntMarie,True,2019-05-31 09:45:00,0.5551,CYTR NK NH clinical update FYI i am sharing news because ALL of soons companies are interelated businesswirecomnewshome
